Maxim Group Increases Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $25.00

Zevra Therapeutics (NASDAQ:ZVRA) had its target price boosted by analysts at Maxim Group from $18.00 to $25.00 in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price target would suggest a potential upside of 231.35% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity Group reduced their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday, September 18th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright upped their price objective on Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, September 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a report on Wednesday, August 14th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Down 8.8 %

Zevra Therapeutics stock opened at $7.55 on Tuesday. The company’s 50-day moving average is $7.12 and its 200-day moving average is $5.74. The firm has a market capitalization of $397.02 million, a PE ratio of -5.59 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. During the same period in the previous year, the company earned ($0.15) earnings per share. Sell-side analysts anticipate that Zevra Therapeutics will post -1.59 earnings per share for the current year.

Insider Buying and Selling

In related news, Director John B. Bode purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The shares were bought at an average price of $5.87 per share, for a total transaction of $58,700.00. Following the completion of the transaction, the director now owns 30,000 shares of the company’s stock, valued at $176,100. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have purchased 22,000 shares of company stock valued at $140,340 over the last 90 days. 2.40% of the stock is owned by corporate insiders.

Institutional Trading of Zevra Therapeutics

Large investors have recently made changes to their positions in the company. Jump Financial LLC acquired a new position in shares of Zevra Therapeutics during the 4th quarter worth $217,000. Focus Financial Network Inc. ADV bought a new position in Zevra Therapeutics in the fourth quarter valued at about $141,000. Armistice Capital LLC bought a new position in Zevra Therapeutics in the fourth quarter valued at about $1,755,000. Virtu Financial LLC acquired a new position in Zevra Therapeutics during the fourth quarter worth about $177,000. Finally, Mystic Asset Management Inc. lifted its holdings in shares of Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock worth $1,545,000 after acquiring an additional 35,514 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.